Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBREXIA-STROKE: Milvexian for Prevention of Recurrent Ischemic Stroke or High-Risk TIA Events
jRCT2031230040Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing Milvexian arm with Placebo arm (2 arms). Primary endpoint: Time to first occurrence of ischemic stroke (overall study period). Started Jun 2023; status: recruiting.
02
Drugs
milvexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on jRCT2031230040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230040.